1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Competitor Analysis: Inhibitors of the bromodomain and extra-terminal domain (BET) family

The Competitive Intelligence Report Inhibitors of the bromodomain and extra-terminal domain (BET) family as of January 201 provides a competitor analysis in the development pipeline of novel small molecule pan, selective or dual target bromodomain and extra-terminal domain (BET) family inhibitors suitable for treatment of cancer, inflammatory and cardiovascular diseases. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.


Bromodomains are epigenetic readers of histone acetylation involved in chromatin remodeling and transcriptional regulation. Bromodomains have attracted great interest as promising new epigenetic targets for diverse human diseases, including inflammation, cancer, and cardiovascular disease. The demonstration that two small molecule compounds, JQ1 and I-BET762, potently inhibit proteins of the bromodomain and extra-terminal (BET) family with potential for cancer and inflammatory disease sparked intense efforts in academia and pharmaceutical industry to develop novel bromodomain antagonists for therapeutic applications. Several BET inhibitors are already in clinical trials for hematological malignancies, solid tumors and cardiovascular disease.


The report includes a compilation of currently active projects in research and development of novel small molecules targeting for treatment of hematologic malignancies, solid tumors, inflammatory and cardiovascular diseases. In addition, the report lists company-specific R&D pipelines of BET Inhibitors. Competitor projects are listed in a tabular format providing Information on:



  • Drug Codes,

  • Target / Mechanism of Action,

  • Class of Compound,

  • Company,

  • Product category/Therapeutic Area,

  • Indication,

  • R&D Stage and

  • additional comments with a hyperlink leading to the source of information.


About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.


Table Of Contents

Competitor Analysis: Inhibitors of the bromodomain and extra-terminal domain (BET) family

Table of Contents



  • Inhibitors of the bromodomain and extra-terminal domain (BET) family

  • Corporate BET Inhibitor Randamp;D Pipelines


View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. - Learn about the types of diagnostic and treatment ...

Lung Cancer: Analytical Tool

August 2016 $ 8096

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.